Susquehanna Fundamental Investments’s Viking Therapeutics VKTX Stock Holding History

Susquehanna Fundamental Investments’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$648K	Buy	+16,620	New	+$537K	0.01%	521
2021 Q2	–	Sell	-72,700	Closed	-$460K	–	1789
2021 Q1	$460K	Buy	+72,700	New	+$511K	0.01%	1173
2020 Q4	–	Sell	-20,000	Closed	-$116K	–	1613
2020 Q3	$116K	Sell	20,000 -1,900	-9%	-$13.1K	﹤0.01%	1266
2020 Q2	$158K	Buy	+21,900	New	+$145K	0.01%	863

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Susquehanna Fundamental Investments's VKTX Position: Q2 2026 in Review

Susquehanna Fundamental Investments opened a new position in Viking Therapeutics (VKTX) in Q2 2026: 16,620 shares worth $648K. The stake represents 0.01% of the portfolio and ranks #521 among its holdings. This is a return to the name: Susquehanna Fundamental Investments previously reported a position in VKTX as recently as Q1 2021.

Susquehanna Fundamental Investments first reported a position in VKTX in Q2 2020 and has held it in 4 quarters since. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

Susquehanna Fundamental Investments held 16,620 shares of Viking Therapeutics worth $648K as of Q2 2026.
Viking Therapeutics was a new Susquehanna Fundamental Investments position in Q2 2026.
Viking Therapeutics made up 0.01% of Susquehanna Fundamental Investments's portfolio in Q2 2026, its #521 holding.
Susquehanna Fundamental Investments first reported a position in Viking Therapeutics in Q2 2020 and has held it in 4 quarters since.
436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2026, filed 14 Aug 2026.